June 18, 2021

Download Ebook Free Overcoming Cancers Resistant To HER-2 Antibodies

Overcoming Cancers Resistant to Her-2 Antibodies

Overcoming Cancers Resistant to Her-2 Antibodies
Author : Benjamin Bonavida
Publisher : Sensitizing Agents for Cancer
Release Date : 2019-12-15
Category : Medical
Total pages :250
GET BOOK

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Therefore, the use of various immunosensitizing agents to reverse resistance has been considered and this book discusses each of them in depth, such as Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer
Author : Benjamin Bonavida
Publisher : Springer Science & Business Media
Release Date : 2013-08-04
Category : Medical
Total pages :202
GET BOOK

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Translational Research in Breast Cancer

Translational Research in Breast Cancer
Author : Dong-Young Noh
Publisher : Springer Nature
Release Date : 2021
Category :
Total pages :129
GET BOOK

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition
Author : Anonim
Publisher : ScholarlyEditions
Release Date : 2012-12-26
Category : Medical
Total pages :105
GET BOOK

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Monoclonal Antibodies. The editors have built Monoclonal Antibodies—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Monoclonal Antibodies in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Monoclonal Antibodies—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
Publisher : Springer
Release Date : 2019-07-15
Category : Medical
Total pages :320
GET BOOK

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Cancer Research

Cancer Research
Author : Anonim
Publisher : Unknown
Release Date : 2006-08
Category : Cancer
Total pages :129
GET BOOK

Targeted Cancer Therapies, From Small Molecules to Antibodies

Targeted Cancer Therapies, From Small Molecules to Antibodies
Author : Zhe-Sheng Chen,Jian-ye Zhang,Yunkai Zhang,Yan-yan Yan
Publisher : Frontiers Media SA
Release Date : 2020-07-22
Category :
Total pages :129
GET BOOK

Recent Developments in Monoclonal Antibody Therapy for Breast Cancer

Recent Developments in Monoclonal Antibody Therapy for Breast Cancer
Author : Brittany Jiang
Publisher : Unknown
Release Date : 2008
Category :
Total pages :56
GET BOOK

Anticancer Research

Anticancer Research
Author : Anonim
Publisher : Unknown
Release Date : 2006
Category : Cancer
Total pages :129
GET BOOK

Indian Journal of Medical Research

Indian Journal of Medical Research
Author : Anonim
Publisher : Unknown
Release Date : 2007
Category : Medicine
Total pages :129
GET BOOK

Tumor Progression and Therapeutic Resistance

Tumor Progression and Therapeutic Resistance
Author : Wafik S. El-Deiry
Publisher : Unknown
Release Date : 2005
Category : Medical
Total pages :198
GET BOOK

This volume presents the entire breadth of translational cancer research and brings together members of academia and industry in the expectation of accelerating interactions and progress in the field. A variety of key topics are presented, beginning with discovery of molecular targets and pathways (oncogene, cell survival, tumor suppression, cell death), host-neoplasm interactions (cell adhesion, matrix proteases), early detection, monitoring progression, understanding tumor progression and metastasis, immune surveillance, in vivo molecular imaging, animal models, drug discovery including chemistry, high-throughput assays, mechanism determination, target validation, therapeutic window and some progress in clinical trials for more advanced agents and targets.

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab
Author : Banujan Balachandran
Publisher : Unknown
Release Date : 2013
Category :
Total pages :129
GET BOOK

"Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab, a humanized monoclonal antibody binding to the extracellular domain of HER-2, has proven to be a beneficial treatment for patients diagnosed as HER-2+ but continues to have limitations. With low response rates for patients when administered alone and for patients having received prior chemotherapy, the true potential of trastuzumab seems to arrive only through combination therapies. However, the majority of advanced HER-2 positive breast cancer patients still develop resistance to the therapy by the end of the first year or present de novo resistance. For this reason, it is important to continue to investigate therapies to give in combination with trastuzumab to improve progression-free survival and overall survival in this clinical setting. Two Phase II Astra Zeneca compounds: AZD0530, a dual Src and Abl kinase inhibitor and AZD8931, a pan-erbb tyrosine kinase inhibitor abrogating EGFR-, HER-2-, and HER-3-mediated signaling were explored in this context using established trastuzumab-naïve and trastuzumab-resistant cell lines. AZD0530 was not effective when administered alone and any combinations with trastuzumab showed positive responses only in those models in which some form of response to AZD0530 alone had been seen. Clinically-relevant responses to AZD8931 were seen in all cell lines tested and for this reason a head-to-head comparison was carried out with lapatinib, the FDA-approved therapy for patients progressing on trastuzumab. AZD8931 alone and in combination with trastuzumab worked effectively to stop proliferation and induce cell death in both trastuzumab-naïve and trastuzumab-resistant cell lines at clinically relevant doses. AZD8931 had similar activity to lapatinib in the SKBR3-based ER-negative cell lines, but was less active in the BT474-based ER-positive cell lines. From this study, it appears AZD8931 is a therapeutic candidate for overcoming trastuzumab resistance but further investigation is required, before translation into the clinical setting, including the use of animal models of trastuzumab-resistance, specifically in the ER-negative subtype." --

Cancer and its Nutritional Therapies

Cancer and its Nutritional Therapies
Author : Dr. Richard A. Passwater's
Publisher : Unknown
Release Date : 1978
Category :
Total pages :129
GET BOOK

Science & Culture

Science & Culture
Author : Anonim
Publisher : Unknown
Release Date : 2004
Category : Electronic journals
Total pages :129
GET BOOK

Drug Resistance in Oncology

Drug Resistance in Oncology
Author : Beverly A. Teicher
Publisher : Marcel Dekker Incorporated
Release Date : 1993
Category : Medical
Total pages :654
GET BOOK

This volume focuses on the mechanisms that involve alterations in cellular biochemistry, properties related to the physiology of the solid tumour mass and changes in the host metabolic status induced by the presence of the tumour - applying this information to the resistance to cancer chemotherapy, radiation therapy and biomodulator therapies. angiogenesis and blood-flow, pH, oxygenation, molecular transport and tissue pressure, oncogenes and tumour-suppressor genes, extracellular matrix and phosphate metabolism; discusses clonal subpopulations, resistance in leukimia, the blood brain barrier, tumour/host interactions and the metastatic phenotype; examines glutathione, metallothionein, glutathione-S-transferases, oxazaphosphorane metabolism, cytochrome P-450, multi-drug resistance and nuclear matrix influence; and presents the effects of antioestrogens, chorionic gonadotropin, transforming and fibroblast growth factors, metastases and radiation resistance.